Viatris (VTRS)

Healthcare · Drug Manufacturers - Specialty & Generic · S&P 500
$17.54 -0.45% on the day Market cap $19.0B 52-week range $9.69 to $18.43 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
-4% a year for 10 years

At a market value of $19.0B, Viatris's free cash flow of $1.9B (fiscal 2025) would need to grow about -4% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 7 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Viatris's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price-4.4% a year
Free cash flow, last 7 years-1.1% a year
Revenue, same period3.4% a year
Price to free cash flow9.8x

Fundamental grade

C

Five factors scored 1 to 9 from VTRS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation8
Profitability2
Growth3
Financial health4
Cash efficiency7

Key numbers

P/E (trailing)—
P/E (forward)6.62x
Price / free cash flow9.82x
EV / EBITDA11.9x
Price / sales1.29x
Price / book1.30x
Revenue growth+5.0%
Operating margin-0.59%
Net margin—
Return on equity—
Dividend yield2.9%
Debt / equity1.46x

Results from SEC filings

Fiscal years, from Viatris's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$17.8B$16.2B$15.4B$14.7B$14.3B
Net income-$1.3B$2.1B$55M-$634M-$3.5B
Free cash flow$2.6B$2.6B$2.5B$2.0B$1.9B
EPS (diluted)-$1.05$1.71$0.05-$0.53-$3.00
Operating margin-0.19%10.0%5.0%0.07%-18.7%

Where the revenue comes from

Revenue by segments, fiscal 2025.

Developed Markets$8.5B60%
Greater China$2.3B16%
Emerging Markets$2.2B16%
JANZ$1.2B8%

Superinvestors who own VTRS

From each investor's latest 13F filing (what a 13F shows). 6 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Larry Robbins
Glenview Capital Management
Added $157M2.9%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $75M0.03%Q2 2026
Joel Greenblatt
Gotham Asset Management
Trimmed $69M0.16%Q2 2026
David Einhorn
Greenlight Capital
New position $36M1.8%Q4 2023
Bill Miller
Miller Value Partners
Added $12M2.8%Q2 2026
Mario Gabelli
GAMCO Investors
Trimmed $3M0.02%Q2 2026

Insider buying

Open-market purchases by Viatris's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$10.71—
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$10.71—
Nov 3, 2025 David S Simmons
213$10.43$2,222

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when VTRS trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Viatris's stock price imply?

At a market value of $19.0B, Viatris would need its free cash flow to grow about -4% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 7 years its free cash flow grew -1% a year.

Are Viatris insiders buying the stock?

3 open-market insider purchases of VTRS in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Viatris?

6 of the superinvestors Investingly tracks hold VTRS in their latest 13F, including Larry Robbins, Cliff Asness, Joel Greenblatt.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.